1[1]De Pierre A. Overview of the role for neoadjuvant therapy for early-stage non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶124-125.
2[2]Albain KS, Pass HI. Induction therapy before surgery for non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶168-171.
3[3]De Pierre A, Milleron B, Chevret S, et al. French phase Ⅲ trial of preoperative chemotherapy (PCT) in resectable stage Ⅰ (except T1N0), Ⅱ, Ⅲa non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶91.
4[4]Splinter T, Groen H, Smit E, et al. Randomized multicenter phase Ⅱ study of chemotherapy followed by surgery versus surgery alone in stage Ⅰand Ⅱ non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶90.
5[5]Eberhardt W, Korfee S, Wagner H, et al. "Minimal N2-disease”(operable) stage ⅢA non-small cell lung cancer: Prospectively randomized multicenter German phase-Ⅲ-trial of surgery (S) followed by adjuvant radiotherapy (RTx) versus "Trimodality treatment”-Early results of feasibility and toxicity in this setting. Lung Cancer,2000,29(Suppl 1)∶95-96.
6[6]Mattson K, Ten Valde G, Krofta K, et al. Early results of an international phase Ⅲ study evaluating Taxotere as neo-adjuvant therapy for radically-treatable stage Ⅲ NSCLC. Lung Cancer,2000,29(Suppl 1)∶90.
7[7]O'Rourke N, Armour A. Neo-adjuvant chemotherapy in stage Ⅲ NSCLC in the West of Scotland improves the potential for cure. Lung Cancer,2000,29(Suppl 1)∶107.
8[8]Saito Y, Minami K, Kobayashi M, et al. Ten years' experience of induction therapy for locally advanced NSCLC; a single institution study. Lung Cancer,2000,29(Suppl 1)∶89-90.
9[9]Abolhoda A, Martin J, Ginsberg RJ, et al. Morbidity and mortality for pulmonary resections in lung cancer after induction treatment. Lung Cancer,2000,29(Suppl 1)∶89.
10[10]Leo F, Solli P, Veronesi G, et al. Pulmonary function changes after induction chemotherapy with cisplatinum and gemcitabine in stage Ⅲ non small cell lung cancer. Any additional risk for surgery? Lung Cancer,2000,29(Suppl 1)∶129-130.
